Search
Clinician Ordering Portal
Scientific evidence
Real-world evidence shows clinicians appropriately use the prognostic 40-gene expression profile (40-GEP) test for high-risk cutaneous squamous cell carcinoma (cSCC) patients
Sep 2022
Treatment decisions for patients with cutaneous squamous cell carcinoma (cSCC) are traditionally based upon clinicopathologic risk factors and staging systems. Due to the accuracy limitations of these resources in predicting poor outcomes, there is a clinically significant need for more accurate methods of risk assessment.
Publication: Cancer Investigation
Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test
Jul 2022
Validation of the integration the 31-GEP testing with clinpath features for invidialized risk assessment of MSS, DMFS, and RFS.
Publication: Journal of the American Academy of Dermatology
An objective fully automated Barrett’s risk prediction assay outperforms most pathologists in risk stratifying Barrett’s esophagus with low-grade dysplasia
May 2022
Conventional pathology review based on histology has limitations, and the TissueCypher BE risk assessment tool can improve the accuracy of prognosis.
Publication: Podium presentation (695) at DDW 2022, San Diego
Efficacy and tolerability of therapies set under pharmacogenetic tools suggestions: A systematic review with meta-analysis about mood disorders
May 2022
An objective fully-automated Barrett's risk prediction assay outperforms most pathologists in risk stratifying Barrett's esophagus with low-grade dysplasia
Apr 2022
Histological review of community-based LGD showed a high inter-observer variability with a signification number of cases classified as non-informative.
Publication: Podium presentation (OP079) at ESGE 2022, Prague
Incorporating the 31-gene expression profile test stratifies survival outcomes and leads to improved survival compared to clinicopathologic factors alone: a surveillance, epidemiology and end results (SEER) program collaboration
Apr 2022
Utilizing patient data provided through collaboration with the NCI SEER program in patients with Stage I-III CM, 31-GEP class result was a significant independent predistor of both MSS and OS. Patients with 31-GEP results in addition to clinicopathologic factors had improved survival.
Publication: Poster, presented at the 18th European Association of Dermato Oncology (EADO) Congress, Seville Spain, April 21-23 2022.
Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th edition staging
Apr 2022
DecisionDx-Melanoma data significantly stratified MSS in stage I, II, and III patients. This test has also demonstrated high specificity and NPV for melanoma-specific mortality (MSM).
Publication: Melanoma Research
Development and validation of a nomogram incorporating gene expression profiling and clinical factors for accurate prediction of metastasis in patients with cutaneous melanoma following MOHS micrographic surgery
Apr 2022
Prospective multicenter study showed that integration of 31-GEP and T stage can gain clinically useful prognostic information from data obtained noninvasively.
Publication: Journal of the American Academy of Dermatology
Expert consensus on the use of prognostic gene expression profiling tests for the management of cutaneous melanoma: consensus from the skin cancer prevention working group
Mar 2022
Expert panel of 8 dermatologists from the Skin Cancer Prevention Working Group developed 6 concensus statements supporting the appropriate use of GEP testing.
Publication: Dermatology and Therapy
Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients
Feb 2022
To improve identification of patients with cutaneous squamous cell carcinoma (SCC) at high risk for metastatic disease, the DecisionDx-SCC assay, a prognostic 40-gene expression profile (40-GEP) test, was developed and validated.
Publication: Diagnostic Pathology
Using a 31-gene expression profile test to stratify patients with stage I–II cutaneous melanoma according to recurrence risk: update to a prospective, multicenter study
Feb 2022
The 31-GEP accurately identified patients with stage IB-II CM at low and high risk of melanoma relapse in a prospective, multicenter study. Identifying which tumors have the highest probability of recurrence or metastasis, despite negative SLN results can aid in earlier disease detection.
Publication: Cancers
Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study
Feb 2022
Final report from a prospective study assessing the impacy of 31-GEP testing results on clinical management decisions including changes in imaging, laboratory work, and frequency of office visits. Outcomes data included.
Publication: Current Medical Research and Opinion